EVGN logo

Evogene (EVGN) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

15 October 2010

Indexes:

Not included

Description:

Evogene is a biotechnology company that focuses on developing innovative solutions for agriculture and health. They use advanced computational biology to enhance crop productivity and create new products, aiming to improve food security and sustainability. Their work includes genetic research and the development of microbial products.

Events Calendar

Earnings

Next earnings date:

Mar 07, 2025

Recent quarterly earnings:

Aug 22, 2024

Recent annual earnings:

Mar 07, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

July 25, 2024

Analyst ratings

Recent major analysts updates

23 Aug '24 Lake Street
Buy
02 Oct '23 Alliance Global Partners
Buy
18 Aug '23 Lake Street
Buy
21 July '23 Roth MKM
Buy
02 May '23 Lake Street
Buy
12 Sept '22 Aegis Capital
Buy
02 Sept '22 Roth MKM
Buy
08 Oct '21 Roth Capital
Buy
29 July '21 Aegis Capital
Buy
01 Dec '20 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
EVGN
seekingalpha.com21 November 2024

Evogene Ltd. (NASDAQ:EVGN ) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Amit Noam - CEO, Lavie BIO Operator Welcome to Evogene's Third Quarter Results Conference Call.

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
EVGN
prnewswire.com12 November 2024

Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season   REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
EVGN
prnewswire.com29 October 2024

The shipment, comprising over 100 tons, was delivered to company's customer in Africa REHOVOT, Israel , Oct. 29, 2024 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company for oil production for bio-based products and biofuel, and a subsidiary of Evogene Ltd.

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
EVGN
prnewswire.com08 October 2024

Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel , Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd.

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
EVGN
prnewswire.com23 August 2024

REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering.

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
EVGN
prnewswire.com12 August 2024

REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
EVGN
prnewswire.com23 July 2024

Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel , July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024.

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
EVGN
prnewswire.com02 July 2024

Lavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season REHOVOT, Israel , July 2, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
EVGN
prnewswire.com25 June 2024

Current castor seed production is expected to support the supply of the new order in 2024, valued at ~ $440K  REHOVOT, Israel , June 25, 2024 /PRNewswire/ -- Casterra Ag Ltd ., a subsidiary of Evogene Ltd.

Evogene Reports First Quarter 2024 Financial Results
Evogene Reports First Quarter 2024 Financial Results
Evogene Reports First Quarter 2024 Financial Results
EVGN
prnewswire.com23 May 2024

Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Evogene?
  • What is the ticker symbol for Evogene?
  • Does Evogene pay dividends?
  • What sector is Evogene in?
  • What industry is Evogene in?
  • What country is Evogene based in?
  • When did Evogene go public?
  • Is Evogene in the S&P 500?
  • Is Evogene in the NASDAQ 100?
  • Is Evogene in the Dow Jones?
  • When was Evogene's last earnings report?
  • When does Evogene report earnings?
  • Should I buy Evogene stock now?

What is the primary business of Evogene?

Evogene is a biotechnology company that focuses on developing innovative solutions for agriculture and health. They use advanced computational biology to enhance crop productivity and create new products, aiming to improve food security and sustainability. Their work includes genetic research and the development of microbial products.

What is the ticker symbol for Evogene?

The ticker symbol for Evogene is NASDAQ:EVGN

Does Evogene pay dividends?

No, Evogene does not pay dividends

What sector is Evogene in?

Evogene is in the Healthcare sector

What industry is Evogene in?

Evogene is in the Biotechnology industry

What country is Evogene based in?

Evogene is headquartered in Israel

When did Evogene go public?

Evogene's initial public offering (IPO) was on 15 October 2010

Is Evogene in the S&P 500?

No, Evogene is not included in the S&P 500 index

Is Evogene in the NASDAQ 100?

No, Evogene is not included in the NASDAQ 100 index

Is Evogene in the Dow Jones?

No, Evogene is not included in the Dow Jones index

When was Evogene's last earnings report?

Evogene's most recent earnings report was on 22 August 2024

When does Evogene report earnings?

The next expected earnings date for Evogene is 7 March 2025

Should I buy Evogene stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions